NF-κB与Survivin基因在脑胶质瘤中的表达

目的探讨细胞核因子KB和Survivin基因在胶质瘤中的表达及其与肿瘤细胞凋亡的关系。方法分别采用原位杂交和免疫组织化学S—P法检测80例星形细胞瘤患者和10例正常脑组织Survivin mRNA和NF—KB的表达，用末端转移标记法（TUNEL）检测肿瘤组织的凋亡并计算其凋亡指数（AI）。结果星形细胞瘤组织中Survivin mRNA的阳性表达率明显高于对照组（P〈0．01），高度恶性组的阳性率明显高于低度恶性组（P〈0．01）；AI在星形细胞瘤中明显高于对照组（P〈0．01），而Survivin mRNA阳性组低于阴性组（P〈0．01）；NF—kB在星形细胞瘤中的表达明显高于对照组（P〈0．01），且Survivin mRNA阳性组明显高于阴性组（P〈0．05）。结论NF-kB与Survivin在星形细胞瘤中的表达密切相关，NF-kB的过表达可能通过上调Survivin mRNA的表达抑制星形细胞瘤细胞的凋亡．从而在肿瘤的发生、发展和治疗中发挥重要作用。     

Survivin、Bcl-2和PTEN在人脑星形细胞瘤中的表达及相关性研究

目的 研究人脑星形细胞瘤中survivin、bcl-2和PTEN的表达情况及相关性，探讨其与星形细胞瘤的发展、临床病理参数之间的关系。方法 应用免疫组织化学Elivision二步法检测实验组与正常对照组标本中survivin、bcl-2和PTEN的表达。结果 survivin、bcl-2和PTEN在不同级别星形细胞瘤中的阳性表达率有显著性差异（P〈0．01）。随着星形细胞瘤病理分级的增加，survivin和bcl-2表达的阳性率及表达强度渐增（P〈0．01），PTEN表达的阳性率及表达强度渐减（P〈0．01）。survivin和bcl-2的表达之间存在正相关关系（P〈0．01）；survivin、bcl-2与PTEN的表达均存在负相关关系（P〈0．01）。结论 在人脑星形细胞瘤中，survivin、bcl-2高表达和PTEN相对低表达，说明三者可能参与人脑星形细胞瘤的病理发展。     

脑星形细胞瘤癌基因表达

52例星形细胞瘤应用免疫组化方法，检测癌基困P^53、C-erbB-2及增殖细胞核抗原(PCNA)的表达，结果发现④p53异常表达率为41.2%(24／52),C-erbB-2过度表达率为39%(20／52)，PCNA(PI>0．05)增殖指数为77%(40／52)，与对照组正常脑组织对比有显差异(P<0.01)。②p53，C-erbB-2，PCNA异常表达与病理级别有明显相关性。病理Ⅲ，Ⅳ级的阳性率分别为80%(16/20)，40%(8／20)，100%(20／20)，(P<0.001)；Ⅱ级的阳性率为33．3％(8／24)，50％(12／24)，83．3%(20／24)，(P<0．01)：Ⅰ级的阳性率为0：③p53阳性组，PCNA指数(PI)；0.552±0.322，阴性组PCNA指数为024±0．308，两组间无差异(P>0．05)；C-erbB-2阳性组，PCNA指数：0．361±0.27，阴性组PCNA指数：0．399±0.39，两组间亦无差异(P>0．05)．④11例胶质增生组织有1例(9％)显示p53表达，C-erbB-2，PCNA无表达：随访3年，病变复发，病理证实为星形细胞瘤Ⅰ～Ⅱ级，C-erbB-2，PCNA表达。结果提示：①星形细胞瘤p53、C-erbB-2及PCNA的异常表达可作为星形细胞瘤恶性程度及病人预后的指标，以p53过度表达尤为重要；②3种抗体的联合应用对星形细胞瘤发病机理研究及预测早癌发生有一定价值，p53异常表达主要是影响星形细胞瘤的分化，而C-erbB-2对肿瘤进展早期起一定作用。③胶质增生的胶质细胞具有恶性表型。     

Moesin在人脑星形细胞瘤的表达及意义

目的探讨膜结构伸展刺突蛋白（Moesin）在人脑星形细胞瘤中的表达及意义。方法应用免疫组织化学链霉菌抗生物素蛋白-过氧化物酶连结法（SP法）,检测56例人脑星形细胞瘤和10例正常脑组织中Moesin和磷酸化Moesin的表达,并结合临床随访资料分析表达水平与星形细胞瘤临床预后的相关性。结果Moesin的阳性表达率在人脑星形细胞瘤组96．4％（54／56）和正常脑组织对照组0％（0／10）之间有统计学差异（P〈0．01）。Ⅲ～Ⅳ级星形细胞瘤Moesin的强阳性表达高于Ⅰ～Ⅱ级,两者相比有统计学差异（χ^3=27．50,P〈0．01）,磷酸化Moesin的表达结果与Moesin的结果基本一致。Moesin强阳性表达组患者比弱阳性＋阴性表达组患者的术后无瘤生存时间短,其差异有统计学意义（χ^2=29．85,P=0．000）。结论Moesin的表达水平与人脑星形细胞瘤的恶性程度密切相关,Moesin的过度表达对星形细胞瘤发展和预后起重要作用,提示Moesin可以作为反映星形细胞瘤预后的一种有价值的分子标志物。     

PCNA和GFAP在脑星形胶质细胞瘤中表达的双重染色研究

目的研究人脑星形胶质细胞瘤中增殖细胞核抗原（PCNA）和胶质纤维酸性蛋白（GFAP）的表达及其与肿瘤分级的关系。方法采用免疫组化双重染色法对41例人脑星形胶质细胞瘤进行PCNA和GFAP两重标记检测。结果脑星形胶质细胞瘤中PCNA与GFAP表达率均为100％，PCNA表达水平与肿瘤分级呈正相关（r=-0．627，P〈0．01），GFAP表达水平与肿瘤分级呈负相关（r=-0．568，P〈0．01）；Ⅰ-Ⅱ级与Ⅲ-Ⅳ级胶质瘤间PCNA和GFAP表达均有显著性差异（P〈0．05）；GFAP表达和PCNA表达水平呈负相关（r=-0．332，P〈0．05）。结论PCNA与GFAP的表达有一定的相关性。PCNA与GFAP的双重表达与脑星形胶质细胞瘤的增殖活性和恶性程度有关。     

AQP-1在星形细胞瘤及瘤周水肿组织中的表达及其意义

目的 探讨人星形细胞瘤及瘤周水肿组织中水通道蛋白-1（AQP—1）的表达及其对瘤周水肿和肿瘤浸润性生长的影响。方法 采用免疫组化SABC法，分析30例星形细胞瘤和瘤周水肿组织中AQP-1的表达。根据MRI结果，采用“多田公式”计算水肿指数（EI）。并以EI评价肿瘤性水肿的程度。结果 AQP—1在低（Ⅰ-Ⅱ级）、高级别（Ⅲ-Ⅳ级）星形细胞瘤中的表达积分光密度值分别为2．76±0．13和6．73±0．18。在对应瘤周水肿组织中分别为4．52±0．08和8．58±0．27，而在正常对照组中几乎无AQP—1表达，三组相较，差异显著（P〈0．05）。EI值在低、高级别组分别为1．59±0．40、3．96±0．85，两组相较，差异显著（P〈0．01）。星形细胞瘤、瘤周水肿组织中AQP-1的表达和肿瘤的EI值均呈正相关（P〈0．01）。结论 AQP—1在星形细胞瘤的侵袭性生长和肿瘤性水肿的发生中可能起重要作用。     

NF-κB与Survivin基因在脑胶质瘤中的表达

目的 探讨细胞核因子κB和Survivin基因在胶质瘤中的表达及其与肿瘤细胞凋亡的关系.方法 分别采用原位杂交和免疫组织化学S-P法检测80例星形细胞瘤患者和10例正常脑组织Survivin mRNA和NF-κB的表达,用末端转移标记法(TUNEL)检测肿瘤组织的凋亡并计算其凋亡指数(AI).结果 星形细胞瘤组织中Survivin mRNA的阳性表达率明显高于对照组(P＜0.01),高度恶性组的阳性率明显高于低度恶性组(P＜0.01);AI在星形细胞瘤中明显高于对照组(P＜0.01),而Survivin mRNA阳性组低于阴性组(P＜0.01);NF-κB在星形细胞瘤中的表达明显高于对照组(P＜0.01),且Survivin mRNA阳性组明显高于阴性组(P＜0.05).结论 NF-κB与Survivin在星形细胞瘤中的表达密切相关,NF-κB的过表达可能通过上调Survivin mRNA的表达抑制星形细胞瘤细胞的凋亡,从而在肿瘤的发生、发展和治疗中发挥重要作用.     

质子磁共振波谱在胶质瘤诊断中的应用

目的 研究质子磁共振波谱（1H Magnetic Resonance Spectroscopy,1HMRS）在胶质瘤诊断及分级中的应用。方法搜集行1HMRS检查并经病理证实的36例胶质瘤患者,其中A组星形胶质细胞瘤Ⅰ～Ⅱ级21例,B组星形胶质细胞瘤Ⅲ～Ⅳ级和多形性胶质母细胞瘤15例。对侧部位的结果作内对照组。观察氮乙酰门氡氨酸（N—acetylaspartate,NAA）、胆碱（choline,Cho）、肌酸（creatine,Cr）、肌醇（Ins）的共振峰及比值。结果A组同对照组间NAA／Cr、NAA／Cho、Cho／Cr差异有统计意义（P〈0．05）。B组同对照组间NAA／Cr、NAA／Cho、Cho／Cr差异有统计意义（P％0．05）。A组与B组间NAA／Cr和NAA／Cho差异有统计意义（P〈0．05）。结论 1HMRS可提高对胶质瘤诊断和分级的准确性。     

脑胶质瘤端粒酶的活性研究

目的 探讨各类脑胶质瘤端粒酶的活性和端粒酶在胶质瘤的恶性程度评估、预后预测等方面的意义。方法 利用TRAP－ELISA方法检测27例胶质瘤中端粒酶的活性，结合肿瘤的病理分类资料进行对照分析。结果 27例胶质瘤中，低级别胶质瘤（星形细胞瘤Ⅰ－Ⅱ级、少胶质细胞瘤和室管膜瘤）14例，端粒酶阳性2例(16．7%)；高级别胶质瘤（呈形细胞瘤Ⅲ－Ⅳ级和间变性室管膜瘤）13例，端粒酶阳性10例（76．9％）。两组之间端粒酶阳性率有显著差异（P＜0．01）。另外，两组之间端粒酶活性定量水平也有显著差异（P＜0．05）。端粒酶阳性组和端粒酶阴性组胶质瘤患者在性别、年龄方面无显著差异（P＞0．05）。10例正常脑组织中未检测到端粒酶活性。结论 端粒酶活性的激活在胶质瘤中是常见的现象。不同恶性程度的胶质瘤，端粒酶活性的阳性率和端粒酶活性水平定量差异显著。端粒酶作为肿瘤标志物，在胶质瘤的恶性程度评估1预后预测等方面具有重要的意义。     

帕金森病纹状体神经元bcl-2/bax的蛋白表达研究

目的 研究帕金森病中纹状体神经元损伤的可能机制。方法 运用免疫组织化学染色法，对比观察bcl-2、bax在帕金森病（PD）大鼠和正常对照组大鼠纹状体神经元中表达征象。采用图像分析技术，定量测定bcl-2、bax的阳性细胞的吸光度（A值）。结果 PD组右侧纹状体神经元bcl-2表达量（A值）较左侧和正常对照组左右侧显著性降低（P＜0．01）；bax表达量较左侧和正常对照组左右侧显著性升高（P＜0．01）；正常对照组左右侧纹状体神经元bcl-2、bax表达量没有显著差异（P＞0．05）。结论 PD中纹状体神经元凋亡过度发生，可能是其损伤机制之一。     

p53 protein alterations in adult astrocytic tumors and oligodendrogliomas

BACKGROUND: p53 is a tumor suppressor gene implicated in the genesis of a variety of malignancies including brain tumors. Overexpression of the p53 protein is often used as a surrogate indicator of alterations in the p53 gene. AIMS: In this study, data is presented on p53 protein expression in adult cases (>15 years of age) of astrocytic (n=152) and oligodendroglial (n=28) tumors of all grades. Of the astrocytic tumors, 86% were supratentorial in location while remaining 14% were located infratentorially - 8 in the the cerebellum and 13 in the brainstem. All the oligodendrogliomas were supratentorial. MATERIALS AND METHODS: p53 protein expression was evaluated on formalin-fixed paraffin-embedded sections using streptavidin biotin immunoperoxidase technique after high temperature antigen retrieval. RESULTS: Overall 52% of supratentorial astrocytic tumors showed p53 immunopositivity with no correlation to the histological grade. Thus, 58.8% of diffuse astrocytomas (WHO Grade II), 53.8% of anaplastic astrocytomas (WHO Grade III) and 50% of glioblastomas (WHO Grade IV) were p53 protein positive. In contrast, all the infratentorial tumors were p53 negative except for one brainstem glioblastoma. Similarly, pilocytic astrocytomas were uniformly p53 negative irrespective of the location. Among oligodendroglial tumors, the overall frequency of p53 immunopositivity was lower (only 28%), though a trend of positive correlation with the tumor grade was noted - 25% in Grade II and 31.5% in grade III (anaplastic oligodendroglioma). Interestingly, p53 labeling index (p53 LI) did not correlate with the histopathological grade in both astrocytic and oligodendroglial tumors. CONCLUSIONS: Thus, this study gives an insight into the genetic and hence biological heterogeneity of gliomas, not only between astrocytic tumors vs. oligodendrogliomas but also within astrocytic tumors with regard to their grade and location. With p53 gene therapy trials in progress, this will possibly have future therapeutic implications.     

Antigen p57/Kip2 as a potential negative regulator of human astrocytoma growth

This study was performed to determine the relationship between p57/Kip2 and the growth of human astrocytomas. Immunohistochemical staining for p57/Kip2, p53, p16, and Ki67 antigen was performed on paraffin-embedded tissue specimens obtained from 36 patients with astrocytoma. Expression of p57/Kip2, p53, p16, and Ki67 antigen was generally increased in association with the astrocytoma tumor grade. Expression of p16 was higher in patients whose tumors express p57/Kip2 in greater than 10% of tumor cells (p < 0.05). Expression of p53 also tended to be higher, but not to a statistically significant extent, in patients whose tumors express p57/Kip2 in greater than 10% of tumor cells. These findings suggest that p57/Kip2 inhibits the growth of human astrocytomas, and may function in parallel with p16 and p53. However, p57/Kip2 is, by itself, insufficient to arrest the cellular proliferation of human astrocytomas.     

Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas

Oligodendrogliomas typically show loss of heterozygosity (LOH) on chromosomes 1p and 19q, which correlates with their response to chemotherapy, whereas low-grade astrocytomas are characterized by frequent TP53 mutations and lack of sensitivity to alkylating therapeutic agents. Unequivocal histological distinction of low-grade diffuse astrocytomas from oligodendrogliomas and oligoastrocytomas is often difficult. To elucidate the relationships between morphological phenotype and genetic profile, we screened 19 oligodendrogliomas (WHO grade II) and 23 low-grade diffuse astrocytomas (WHO grade II) for TP53 mutations and LOH on 1p and 19q. In oligodendrogliomas, LOH on chromosomes 1p and/or 19q was found in 15 cases (79%) and TP53 mutation was detected in 4 cases (21%). The presence of a typical perinuclear halo in >50% of tumour cells and a chicken-wire vascular pattern were significantly associated with LOH on 1p or 19q (93% of cases). This suggests that oligodendrogliomas with classical histologic features are likely to have a better prognosis. In low-grade diffuse astrocytomas, LOH on chromosomes 1p and/or 19q was found in three cases (13%) and TP53 mutation was detected in ten cases (43%). Histologically, five low-grade astrocytomas (22%) contained small areas with oligodendroglial differentiation, but this did not correlate with the presence of TP53 mutations or LOH on 1p and 19q. In both oligodendrogliomas and astrocytomas, LOH on chromosomes 1p or 19q and TP53 mutation were mutually exclusive. Methylation of the promoter of the gene for O (6)-methylguanine-DNA methyltransferase (MGMT), a DNA repair protein, which confers resistance to chemotherapy with alkylating agents, was detected in 47% of oligodendrogliomas and 48% of low-grade diffuse astrocytomas. There was no correlation with LOH on chromosomes 1p/19q, suggesting that MGMT may not be a prognostic marker for oligodendrogliomas.     

The spectrum of long-term epilepsy-associated tumors: long-term seizure and tumor outcome and neurosurgical aspects

PURPOSE: To describe the histologic spectrum and clinical characteristics of patients with neuroepithelial tumors and drug-resistant epilepsy and to analyze clinical data and treatment related to seizure outcome and survival. METHODS: Data were analyzed from 207 consecutive patients with intractable epilepsy (aged 2-54 years), who between 1988 and 1999 had >or=50% resection of supratentorial, neuroepithelial tumors. Extent of resection was assessed on postoperative magnetic resonance imaging (MRI); seizure outcome was classified according to Engel's outcome scale; and follow-up data were prospectively updated. RESULTS: Median follow-up was eight years (range, 2-14 years). Histologic examination revealed 154 classic epilepsy-associated tumors (ganglioglioma, dysembryoplastic neuroepithelial tumor, pleomorphic xanthoastrocytoma, and pilocytic astrocytomas) and 53 others (astrocytomas and oligodendrogliomas). Four World Health Organization (WHO) grade III tumors were found (astrocytoma, n = 3; ganglioglioma, n = 1). After surgery, 82% of the patients were seizure free (class I). The following factors were associated with improved seizure outcome: Short duration of epilepsy before surgery, single EEG focus, absence of additional hippocampal sclerosis or cortical dysplasia, transsylvian approach, other than astrocytomas, and complete tumor resection. After 5 years, only nine (4%) patients had tumor recurrence, four (2%) with malignant transformation and death. None of the four patients with anaplastic tumors died. Even patients with astrocytomas of WHO grade II or III showed 10-year recurrence of only 25% and 10-year survival of 90%. CONCLUSIONS: Tumors associated with long-term epilepsy should be removed early for two different reasons: high rate of seizure freedom and rare but potential risk of malignant tumor progression. The unexpected long survival of these astrocytomas should be investigated by using immunohistochemistry and molecular biology.     

Desmoplastic infantile ganglioglioma – clinicopathological and immunohistochemical study of four cases

CASE REPORTS: Four cases of desmoplastic infantile ganglioglioma (DIG) seen in India are described. These patients presented with large, supratentorial, superficially situated cystic tumours that showed glial and ganglionic differentiation; accompanied by a severe desmoplastic reaction. MIB-1 labelling was rare, despite foci of apparently primitive neuroepithelial cells. There was lacking p53 protein expression by tumour cells in all cases. The prognosis was good following either partial or complete tumour resection. DIGs are a distinct form of developmental neuroepithelial tumour, probably arising from neural progenitor cells in subcortical zone along with mature subpial astrocytes. CONCLUSIONS: In view of its favourable prognosis, this tumour has to be diagnosed accurately by immunohistochemical techniques using glial and neuronal markers. The absence of p53 protein expression suggests that DIG probably has different molecular genetic pathways from other supratentorial astrocytomas.     

Gliomas of the optic nerve: histological, immunohistochemical (MIB-1 and p53), and MRI analysis

Gliomas of the optic nerve, although typically of pilocytic (WHO grade I) histology, can present within the spectrum of astrocytic neoplasia including glioblastoma (WHO grade IV). In certain cases, histologic features alone make the distinction between pilocytic and diffuse astrocytomas difficult. We reviewed 22 cases of optic nerve gliomas, 19 of which were pilocytic astrocytomas (PA), and 3 of which were diffuse, non-pilocytic astrocytomas. The cases were evaluated for their clinical course, radiographic appearance, histologic grade, and proliferation indices as detected by MIB-1 (Ki-67) and p53 antibodies. Of the 19 PA, 14 showed no tumor growth by magnetic resonance imaging, and had Ki-67 and p53 labeling indices (LI) of < 1%. The other 5 PA exhibited aggressive behavior manifest by marked diffuse infiltrative tumor growth causing death in 2 patients, 1 of whom was diagnosed with neurofibromatosis type 1 (immunoperoxidase and radiographs not available), and marked local growth with an average time to growth of 39.3 months, a Ki-67 LI of 2–3%, and a p53 LI of < 1% in three others. Three of the five aggressive PA histologically demonstrated a finely reticulated pattern, a pattern that appears as an exaggeration or expansion of the normal neuroglia of the optic nerve, and may simulate a diffuse low-grade astrocytoma. Two demonstrated the coarsely reticulated pattern, with the biphasic and microcystic pattern typical of PA. Three diffuse astrocytomas (2 anaplastic astrocytomas and 1 glioblastoma) originated clinically and radiographically from the optic nerve, and revealed a Ki-67 LI of 2–12%, a p53 LI of 2–8%, and an average time to growth of 8 months. We conclude that the majority of PA of the optic nerve are non-aggressive, stabilize radiographically, and have Ki-67 and p53 LI < 1%. However, a subpopulation of PA has a propensity for aggressive behavior, and are identified by a Ki-67 LI of 2–3% and a p53 LI of < 1%. Diffuse astrocytomas have both Ki-67 and p53 LI > 2%. Thus, in cases of aggressive optic nerve tumors in which the histologic review of biopsy material cannot confidently confirm the diagnosis of pilocytic or diffuse fibrillary glioma, a p53 LI of > 1% appears to favor the diagnosis of diffuse astrocytoma. Received: 18 May 1999 / Revised: 10 August 1999 / Accepted: 18 August 1999     

血管外膜细胞瘤p53和Ki-67的表达与肿瘤分级和复发的关系

目的 探讨中枢神经系统血管外膜细胞瘤(HPC)中p53及Ki-67的表达与肿瘤的分级和复发的关系. 方法 回顾性分析北京天坛医院自2005年1月采用至2008年1月手术切除治疗的97例中枢神经系统HPC患者的临床资料,HE染色97例FIPC标本并按照WHO标准进行分级;免疫组织化学染色检测并比较不同分级、复发和未复发肿瘤标本中p53和Ki-67的表达.结果 HE染色检测显示HPC分级Ⅱ级74例,Ⅲ级23例;随访结果显示未复发HPC 49例,复发39例;免疫组化检测结果显示Ⅱ级HPC中p53和Ki-67阳性细胞数均明显低于Ⅲ级,未复发病例的Ki-67和p53阳性细胞数均明显低于复发病例,差异均有统计学意义(P<0.05).结论 Ki-67、p53的表达越高,HPC的组织分级越高,复发风险越高,可作为判断HPC患者预后的指标.     

14-3-3蛋白在星形细胞瘤中的表达及意义

目的探讨14-3-3蛋白在星形细胞瘤中的表达与肿瘤病理分级和预后间的关系。方法采用免疫组化ABC法检测10例正常脑组织和67例确诊并有随访的人脑星形细胞瘤石蜡标本中14-3-3蛋白的表达情况。分析14-3-3蛋白的表达与肿瘤恶性程度及预后间的关系。结果在正常脑组织标本中，14-3-3蛋白主要表达于神经元胞体和突起，而在少数的胶质细胞中仅见其弱表达。绝大部分星形胶质细胞瘤中可见14-3-3蛋白阳性表达，其阳性表达率为：Ⅱ级76．5％（13／17），Ⅲ级76．2％（16／21），Ⅳ级79．3％（23／29）。不同恶性级别的星形细胞肿瘤中，14-3-3蛋白的阳性表达率无显著差别（P〉0．05），但14-3-3蛋白表达的强度和范围有随肿瘤的恶性度增高而增加的趋势（P〈0．05）。52例14-3-3蛋白阳性表达患者的生存期明显短于15例14-3-3蛋白表达阴性的患者（P〈0．01）。结论14-3-3蛋白在人脑星形细胞瘤中的表达上凋与肿瘤的恶性程度及预后相关。14-3-3蛋白有望成为星形细胞瘤基因治疗的新靶点。     

Bcl-2和Bax蛋白在人脑星形细胞瘤中的表达及意义

目的　研究 Ｂｃｌ２ 和 Ｂａｘ 蛋白与人脑星形细胞瘤发生的关系。方法　收集人脑星形细胞瘤标本５８ 例, 行 Ｓ Ｐ 染色。结果　 Ｂｃｌ２ 在星形细胞瘤中阳性表达率为５６９ ％ , 且表达率随肿瘤恶性程度的增加而增高。 Ｂａｘ 的表达率为５５２ ％ , 显著高于对照组。 Ｂｃｌ２ 表达阳性的肿瘤中 Ｂａｘ 蛋白表达率（６６７ ％ ） 显著高于 Ｂｃｌ２ 表达阴性的肿瘤（４００ ％ ） 。结论　 Ｂｃｌ２ 和 Ｂａｘ 蛋白的表达与星形细胞瘤的发生和发展有较密切的关系, 且它们在星形细胞瘤的发生中可能存在相互作用的关系。